A Study to Evaluate the Effectiveness of Long-acting (LA) Cabotegravir (CAB) + Rilpivirine (RPV) LA When Given to Participants With Detectable HIV-1 (NCT06694805)
A Phase 3b, Open Label, Randomized, standard-of Care Control Arm, Multicenter, Superiority Study Evaluating the Efficacy, Safety, and Tolerability of Injectable CAB LA + RPV LA in Viremic Participants Living With HIV-1 (CROWN)
🩺 Plain-English Summary (8th-Grade Level)
This study will assess how effective, safe, and long-lasting a long-acting antiretroviral therapy (ART) using CAB LA + RPV LA is for people with HIV who still have detectable virus levels despite being on oral ART. The study will also consider feedback from patients on their experience with this treatment.
Who can join: Review the eligibility criteria below.
Location: GSK Investigational Site — Birmingham, Alabama
Age range: 12 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (85 Sites)
Showing the first 25 of 85 sites.
- GSK Investigational Site — Birmingham, Alabama
- GSK Investigational Site — Los Angeles, California
- GSK Investigational Site — Los Angeles, California
- GSK Investigational Site — Los Angeles, California
- GSK Investigational Site — Aurora, Colorado
- GSK Investigational Site — Denver, Colorado
- GSK Investigational Site — New Haven, Connecticut
- GSK Investigational Site — Newark, Delaware
- GSK Investigational Site — Washington D.C., District of Columbia
- GSK Investigational Site — Jacksonville, Florida
- GSK Investigational Site — Miami, Florida
- GSK Investigational Site — Sarasota, Florida
- GSK Investigational Site — West Palm Beach, Florida
- GSK Investigational Site — Atlanta, Georgia
- GSK Investigational Site — Decatur, Georgia
- GSK Investigational Site — Macon, Georgia
- GSK Investigational Site — Chicago, Illinois
- GSK Investigational Site — Chicago, Illinois
- GSK Investigational Site — Chicago, Illinois
- GSK Investigational Site — Baltimore, Maryland
- GSK Investigational Site — Baltimore, Maryland
- GSK Investigational Site — Boston, Massachusetts
- GSK Investigational Site — Berkley, Michigan
- GSK Investigational Site — Kansas City, Missouri
- GSK Investigational Site — St Louis, Missouri
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in HIV Infections
- Testing a Real-time Electronic Antiretroviral Adherence Monitoring Intervention — Chicago, Illinois
- The Ganchero Intervention for Migrant People Who Inject Drugs From Puerto Rico in New York City — New York, New York
- Efficacy, Safety and Tolerability Study of Long-acting Cabotegravir Plus Long-acting Rilpivirine (CAB LA + RPV LA) in Human-immunodeficiency Virus-1 (HIV-1) Infected Adults — Birmingham, Alabama
- Clinical Decision Support for PrEP — Los Angeles, California
- Peer Supported Collaborative Care Mental Health and Substance Use Disorder Care — Baltimore, Maryland
- A Study to Assess the Safety and Pharmacokinetics of a Human Monoclonal Antibody (VH4527079) in Healthy Adults and Persons With HIV — Las Vegas, Nevada
Explore by condition: All HIV Infections clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.